<DOC>
	<DOCNO>NCT00491868</DOCNO>
	<brief_summary>This study use comparative drug ( epoetin beta ) ass efficacy safety intravenous injection R744 renal anemia patient Hemodialysis patient .</brief_summary>
	<brief_title>Clinical Study R744 Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients receive hemodialysis 3 time week least 12 week registration Patients age ≥ 20 year time obtain consent Patients receive rHuEPO preparation least week least 8 week registration Within 4 week registration , patient receive rHuEPO preparation 750IU ( 3 time week ) , 1,500IU ( twice week ( 1st 2nd hemodialysis day week , or1st 3rd hemodialysis day week ) ) , 1,500IU ( 3 time week ) , 3,000IU ( twice week ( 1st 2nd hemodialysis day week , or1st 3rd hemodialysis day week ) ) , patient change dosage administration . Patients whose predialysis Hb concentration ≥ 9.0 g/dL ≤12.0 g/dL mean value predialysis Hb concentration ≥ 9.5 g/dL ≤11.5 g/dL determine begin week within 8 week registration Patients whose transferrin saturation ≥ 20 % ferritin ≥ 100ng/mL time point within 8 week registration Patients hardly controllable hypertension ( patient whose diastolic blood pressure ≥ 100 mmHg 1/3 determine occasion within 12 week registration ) Patients congestive cardiac failure ( ≥ Class III NYHA cardiac function classification ) Female patient pregnant , lactate , possibly pregnant willing take contraceptive measure period day start treatment study drug 90 day day last dose study drug Patients complication myocardial infarction , pulmonary infarction cerebral infarction ( exclude asymptomatic cerebral infarction ) Patients confirm serious allergy serious drug allergy ( shock , anaphylactoid symptom ) Patients hypersensitive rHuEPO preparation Patients malignant tumor ( include hemic malignant tumor ) , severe infection , systemic hemic disease ( osteomyelodysplasia syndrome , hemoglobinopathy , etc . ) , hemolytic anemia apparent hemorrhagic lesion digestive tract hemorrhage Patients receive anabolic hormone preparation , testosterone enanthate , testosterone propionate , methyltestosterone mepitiostane within 12 week registration Patients receive another investigational drug within 12 week registration Patients receive R744 registration Patients whose AST ( GOT ) value ≥ 100 IU/L ALT ( GPT ) value ≥ 100 IU/L registration Patients receive erythrocyte transfusion within 16 week registration Patients surgical operation accompany mark bleed plan study period In addition , patient judge ineligible participate study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>